Vivos Therapeutics (VVOS) Common Equity (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Common Equity data on file, last reported at -$1.1 million in Q1 2026.

• On a quarterly basis, Common Equity fell 125.82% year-over-year to -$1.1 million in Q1 2026; TTM through Mar 2026 was -$1.1 million, a 125.82% decrease from a year earlier, with the FY2025 full-year figure at -$1.5 million, down 119.49% from the prior year.
• Common Equity for Q1 2026 stood at -$1.1 million, up from -$1.5 million in the prior quarter.
• Over the last five years, Common Equity for VVOS reached as high as $21.0 million in Q1 2022 and fell as low as -$1.5 million in Q4 2025.
• Historically, Common Equity has averaged $5.4 million across 5 years, with a median of $4.6 million in 2025.
• Across the five-year window, Common Equity jumped 16563.04% in 2024 and plunged 125.82% in 2026, its largest moves.
• Year by year, Common Equity stood at $4.8 million in 2022, then sank by 91.44% to $411000.0 in 2023, then soared by 1835.28% to $8.0 million in 2024, then slumped by 119.49% to -$1.5 million in 2025, then increased by 26.58% to -$1.1 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$1.1 million in Q1 2026, -$1.5 million in Q4 2025, and $2.5 million in Q3 2025.